-
Something wrong with this record ?
Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor β: a structure-based approach for cancer therapy
I. Habib, MN. Sulaimani, DS. Jairajpuri, A. Hussain, T. Mohammad, MF. Alajmi, A. Shamsi, MI. Hassan
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2014
Free Medical Journals
from 2014
PubMed Central
from 2014
Europe PubMed Central
from 2014
Open Access Digital Library
from 2014-01-01
Open Access Digital Library
from 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2014
- Publication type
- Journal Article MeSH
Platelet-derived growth factor receptor beta (PDGFRβ) belongs to the receptor tyrosine kinase (RTK) protein family and is implicated in several disorders such as hematopoietic, glial, and soft-tissue cancer, non-cancerous disorders, including skeletal defects, brain calcification, and vascular anomalies. The research on small molecule inhibitors targeting PDGFRβ in cancer treatment has seen promising developments, but significant gaps remain. PDGFRβ, receptor tyrosine kinase, is overexpressed in various cancers and plays an important role in tumor progression, making it a potential therapeutic target. However, despite advances in identifying and characterizing PDGFRβ inhibitors, few have progressed to clinical trials, and the mechanistic details of PDGFRβ's interactions with small molecule inhibitors are still not fully understood. Moreover, the specificity and selectivity of these inhibitors remain challenging, as off-target effects can lead to unwanted toxicity. In this investigation, two compounds, Genostrychnine and Chelidonine, were discovered that help inhibit the kinase activity of PDGFRβ. These small molecules were identified by employing various parameters involved in the drug discovery process, such as Lipinski's rule of five (RO5), 2D similarity search and 3D pharmacophore-based virtual screening followed by MD simulation studies. The identified molecules were found to be effective and significantly bound with the PDGFRβ kinase domain. Overall, our findings demonstrate that these small drug-like compounds can be beneficial tools in studying the properties of PDGFRβ and can play a crucial role in the therapeutic development of cancers and other associated diseases.
Centre for Interdisciplinary Research in Basic Sciences New Delhi India
Department of Parasitology Faculty of Science University of South Bohemia Ceske Budejovice Czechia
Department of Pharmacognosy College of Pharmacy King Saud University Riyadh Saudi Arabia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002353
- 003
- CZ-PrNML
- 005
- 20250123101851.0
- 007
- ta
- 008
- 250117e20241015sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fmolb.2024.1492847 $2 doi
- 035 __
- $a (PubMed)39473823
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Habib, Insan $u Department of Parasitology, Faculty of Science, University of South Bohemia, Ceske Budejovice, Czechia $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
- 245 10
- $a Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor β: a structure-based approach for cancer therapy / $c I. Habib, MN. Sulaimani, DS. Jairajpuri, A. Hussain, T. Mohammad, MF. Alajmi, A. Shamsi, MI. Hassan
- 520 9_
- $a Platelet-derived growth factor receptor beta (PDGFRβ) belongs to the receptor tyrosine kinase (RTK) protein family and is implicated in several disorders such as hematopoietic, glial, and soft-tissue cancer, non-cancerous disorders, including skeletal defects, brain calcification, and vascular anomalies. The research on small molecule inhibitors targeting PDGFRβ in cancer treatment has seen promising developments, but significant gaps remain. PDGFRβ, receptor tyrosine kinase, is overexpressed in various cancers and plays an important role in tumor progression, making it a potential therapeutic target. However, despite advances in identifying and characterizing PDGFRβ inhibitors, few have progressed to clinical trials, and the mechanistic details of PDGFRβ's interactions with small molecule inhibitors are still not fully understood. Moreover, the specificity and selectivity of these inhibitors remain challenging, as off-target effects can lead to unwanted toxicity. In this investigation, two compounds, Genostrychnine and Chelidonine, were discovered that help inhibit the kinase activity of PDGFRβ. These small molecules were identified by employing various parameters involved in the drug discovery process, such as Lipinski's rule of five (RO5), 2D similarity search and 3D pharmacophore-based virtual screening followed by MD simulation studies. The identified molecules were found to be effective and significantly bound with the PDGFRβ kinase domain. Overall, our findings demonstrate that these small drug-like compounds can be beneficial tools in studying the properties of PDGFRβ and can play a crucial role in the therapeutic development of cancers and other associated diseases.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sulaimani, Md Nayab $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
- 700 1_
- $a Jairajpuri, Deeba Shamim $u Department of Medical Biochemistry, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain
- 700 1_
- $a Hussain, Afzal $u Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
- 700 1_
- $a Mohammad, Taj $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
- 700 1_
- $a Alajmi, Mohamed F $u Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
- 700 1_
- $a Shamsi, Anas $u Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates
- 700 1_
- $a Hassan, Md Imtaiyaz $u Centre for Interdisciplinary Research in Basic Sciences, New Delhi, India
- 773 0_
- $w MED00188065 $t Frontiers in molecular biosciences $x 2296-889X $g Roč. 11 (20241015), s. 1492847
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39473823 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123101845 $b ABA008
- 999 __
- $a ok $b bmc $g 2254549 $s 1238356
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 11 $c - $d 1492847 $e 20241015 $i 2296-889X $m Frontiers in molecular biosciences $n Front Mol Biosci $x MED00188065
- LZP __
- $a Pubmed-20250117